BRIEF-J&J Says Nipocalimab Granted U.S. FDA Priority Review For Treatment Of Generalized Myasthenia Gravis
ReutersJan 9, 2025 2:42 PM
Jan 9 (Reuters) - Johnson & Johnson JNJ.N:
J&J: NIPOCALIMAB GRANTED U.S. FDA PRIORITY REVIEW FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG)
Source text: [ID:]
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com))
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Related Articles
What Impact Will California Wildfires Have on The Stock Market?
TradingKey - Right now in the US, there are ferocious wildfires that are destroying acres of both land and homes in California. Being spread by strong winds, the fires are also heading towards major urban centres, like Los Angeles.TradingKey
8 hours ago
Gold Stocks: Should Investors Consider Buying Them?
TradingKey - While global stock markets and Bitcoin are close to all-time highs, there are also other assets out there that investors should consider.TradingKey
9 hours ago
Trump’s Agenda Already Faces Irresistible Forces
WASHINGTON, Jan 8 (Reuters Breakingviews) - President-elect Donald Trump’s legislative agenda faces roadblocks before he even takes office. Despite his Republican Party controlling all branches of the federal government, resolving a once-in-a-decade fight over the tax code as well as immigration...Reuters
16 hours ago
Why Did Red-Hot Quantum Computing Stocks Just Plunge Over 40%?
TradingKey - Unless you’ve been living under a rock in the last few months of 2024, most investors will have been aware that quantum computing stocks were on fire. Given the hype surrounding the breakthrough of the “Willow” quantum computing chip by Alphabet Inc (NASDAQ: GOOGL), quantum computing stTradingKey
16 hours ago
